| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.05 |